triple agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-22. Anything still debated is marked as such rather than presented as settled.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
=== Uptake === Glucose binds to the taste receptor for sweetness on the human tongue, specifically, the proteins T1R2 and T1R3, thus allowing human to identify glucose-containing food sources. Glucose mainly comes from food—about 300 g (11 oz) per day is produced by conversion of food, but it is also synthesized from other metabolites in the body's cells. In humans, the breakdown of glucose-containing polysaccharides happens in part already during chewing by means of amylase, which is contained in saliva, as well as by maltase, lactase, and sucrase on the brush border of the small intestine. Glucose is a building block of many carbohydrates and can be split off from them using certain enzymes. Glucosidases, a subgroup of the glycosidases, first catalyze the hydrolysis of long-chain glucose-containing polysaccharides, removing terminal glucose. In turn, disaccharides are mostly degraded by specific glycosidases to glucose. The names of the degrading enzymes are often derived from the particular poly- and disaccharide; among other things, for the degradation of polysaccharide chains there are amylases (named after amylose, a component of starch), cellulases (named after cellulose), chitinases (named after chitin), and more. Furthermore, for the cleavage of disaccharides, there are maltase, lactase, sucrase, trehalase, and others. In humans, about 70 genes are known that code for glycosidases. They have functions in the digestion and degradation of glycogen, sphingolipids, mucopolysaccharides, and poly (ADP-ribose) polymerases.
AMP deaminase deficiency (formally known as myoadenylate deaminase deficiency or MADD) is a metabolic myopathy which results in excessive AMP buildup brought on by exercise. AMP deaminase is needed to convert AMP into IMP in the purine nucleotide cycle. Without this enzyme, the excessive AMP buildup is initially due to the adenylate kinase (myokinase) reaction which occurs after a muscle contraction. However, AMP is also used to allosterically regulate the enzyme myophosphorylase (see Glycogen phosphorylase § Regulation), so the initial buildup of AMP triggers the enzyme myophosphorylase to release muscle glycogen into glucose-1-P (glycogen→glucose-1-P), which eventually depletes the muscle glycogen, which in turn triggers protein metabolism, which then produces even more AMP. In AMP deaminase deficiency, excess adenosine is converted into uric acid in the following reaction:
== Research == Some of Patton's earliest research in collaboration with D. V. Josephson revealed that a change in methionine in milk was responsible for the off flavor produced when milk is exposed to light. In other of his early work Patton discovered that malonic dialdehyde is a product of lipid oxidation and the basic reactant in the thiobarbituric acid and Kreis tests for lipid oxidation. One of the first to use gas chromatography, mass spectrometry and thin layer chromatography in flavor research, Patton proved, using these techniques, that methyl sulfide is a key component in the flavor of milk, methods his student Allen Day, who went on to become vice-president for research at IFF, put to good use. At Penn State, "in the 1960s and 1970s, Patton would lead a departmental redirection into lipid research with important insights on mammary gland milk fat synthesis,” but he attributed the turn in his research from the characterization of milk lipids to milk synthesis and secretions to Robert McCarthy. Patton's research in this area is summarized in Biomedical Aspects of Lactation. While lipid research continued to be a focus of Patton's investigations on the various expeditions he participated on with Andrew Benson, (for example, the importance of triglyceride in the salmon's heart function; the chemical characterization of unique lipids in marine animals), an investigation that demonstrated the high food value of the red tide organism (the phytoplankton bloom), remains under explored.
Nutt has published studies praising the potential of pagoclone which were financed by Indevus which was seeking funding for a possible production of the compound. The long-term safety of pagoclone has not been assessed. The abuse potential of pagoclone has been assessed as being similar to, or slightly less than that of diazepam and it would also be expected to be somewhat safer due to its relatively weaker sedative effects, but development of pagoclone as a commercial drug would still be unlikely due to concerns about abuse. Pagoclone was trialed as a drug to improve speech fluency as a treatment for stuttering, but research for this application was discontinued following disappointing results in Phase II clinical trials.
==== Warp Drive Bio ==== In 2012, Verdine founded Warp Drive Bio with cofounders George Church and James Wells. The company maps the genomes of soil-dwelling microbes in the search for potential treatments for drug-resistant ailments. In 2013, Verdine became full-time CEO of Warp Drive Bio, then handed the CEO position to Lawrence Reid in 2016 in order to found two new startups, FogPharma and LifeMine.
Sources: en.wikipedia.org
== Revocation of nursing license == After the incident, the Tennessee Board of Nursing reviewed Vaught's case and initially rendered "a decision that [the] matter did not merit further action." However, In September 2019, the Tennessee Department of Health's Board of Nursing reversed their decision, charging Vaught with three infractions: unprofessional conduct, abandoning or neglecting a patient who required care, and failing to maintain an accurate patient record. In July 2021, the nursing board revoked Vaught's license and fined her $3,000. During her testimony, she took responsibility for the error, but also described procedural issues at the hospital. "Overriding was something we did as a part of our practice every day. You couldn't get a bag of fluids for a patient without using an override function." The Institute for Safe Medication Practices called the board decision "disturbing and unjust." It alleged that the decision reflected "significant outcome bias," "inability to differentiate between human error, at-risk behavior, and reckless behavior," "lack of a thorough investigation," and other shortcomings.
This reference follows the "Dieselgate" scandal where Volkswagen and manufacturers around Europe and the world fraudulently concealed their true emissions. In 2007, Commission v Germany held that the German Volkswagen Act 1959 violated free movement of capital in TFEU article 63 by ensuring that the state of Lower Saxony had a golden share to exercise public control over the company's governance. It limited voting rights of individual shareholder to 20% of the company. The German government's justification that the restrictions were an overriding public interest, for instance, to protect workers was rejected. A justification for environmental protection was not offered. After this, the Porsche family dominated Volkswagen, and in 2007 a new CEO, Martin Winterkorn took up his post and aimed in 'Strategie 2018' to become the world's largest auto-manufacturer, and it began to install cheat devices.
In response to an attack by supporters of former President Bolsonaro on the Praça dos Três Poderes, Lula announced that he had signed a decree declaring a state of emergency in the Federal District until the end of January.
== External links == Controlled vocabulary of post-translational modifications in Uniprot List of posttranslational modifications in ExPASy Browse SCOP domains by PTM — from the dcGO database Overview and description of commonly used post-translational modification detection techniques
Sources: en.wikipedia.org
February 4: Abolition of slavery in French colonies (not applied in some later-acquired colonies; slavery reestablished in most colonies from 1802, except Saint-Domingue, independent in 1804). March 12: Possibility to annul religious vows made before age 18 for girls or 21 for boys. 1795
=== Sheep meat consumption === According to the OECD-FAO Agricultural Outlook for 2016, the top consumers of sheep meat in 2015 were as follows: EU countries are not individually surveyed in this list. Among EU nations, Greece is the per capita leader in consumption at 12.3 kg, with Cyprus following right after, while the UK's annual per capita lamb consumption is 4.7 kg. Outside of the OECD, the largest per capita consumer overall is Mongolia, with 45.1 kg.
Sickle cell disease (SCD), also simply called sickle cell, is a group of inherited hemoglobin-related blood disorders. Sickle cell disease is caused by an abnormality in the oxygen-carrying protein haemoglobin found in red blood cells. This leads to the red blood cells adopting an abnormal sickle-like shape under certain circumstances. With this shape, they cannot deform as they pass through capillaries, causing blockages. Problems in sickle cell disease typically begin around 5 to 6 months of age. Several health problems may develop, such as attacks of pain (known as a sickle cell crisis) in joints, anaemia, swelling in the hands and feet, bacterial infections, dizziness and stroke. The probability of severe symptoms, including long-term pain, increases with age. Without treatment, people with sickle cell disease rarely reach adulthood, but with good healthcare, median life expectancy is between 58 and 66 years. All of the major organs are affected by sickle cell disease. The liver, heart, kidneys, lungs, gallbladder, eyes, bones, and joints can be damaged by abnormal sickle cells and their inability to flow through the small blood vessels. Sickle cell disease occurs when a person inherits two abnormal copies of the β-globin gene that make haemoglobin, one from each parent. The abnormal gene generates haemoglobin S (HbS) which changes the properties of red blood cells.
Amitay (1958), lobbyist, former executive director of the American Israel Public Affairs Committee and vice chairman of the Jewish Institute for National Security Affairs Richard Grossman (1965), critic and organizer against corporate power, former director of Greenpeace USA Brian Flanagan (1968), former member of the Students for a Democratic Society and Weather Underground David Gilbert (1966), leader of Students for a Democratic Society and participant in the deadly 1981 Brink's robbery with Kathy Boudin, the mother of his child Chesa Boudin Ted Gold* (1968), student activist, leader of the Students for a Democratic Society and member of the Weatherman group who died in the 1970 Greenwich Village townhouse explosion John Jacobs (1969), student activist, member of Students for a Democratic Society and the Weather Underground, went into hiding after the fatal 1970 Greenwich Village townhouse explosion Mark Rudd (1969), president of Students for a Democratic Society and member of the Weather Underground Stephen Donaldson (1970), bisexual political activist, founder of the Student Homophile League at Columbia, the oldest college LGBTQ organization in the world David Kaczynski (1970), anti-death penalty activist, brother of Unabomber Theodore Kaczynski Robert Roth* (1970), activist associated with the Students for a Democratic Society Sheena Wright (1990), CEO of the United Way of New York City David Kaiser (1991), philanthropist, environmental activist, president of the Rockefeller Family Fund, great-great-grandson of John D.
=== Expansion === SHIELD Illinois was originally intended to be a facilitator, assisting laboratories in preparing to use the covidSHIELD assay and advising colleges, universities, and other organizations on how to collect specimens. SHIELD Illinois would also provide the technology needed to transmit orders to the lab and results back to the collecting agency. It was estimated that the program would have 50 testing locations and collect 1.5 million tests over a six-month period. Over time, SHIELD Illinois's role expanded beyond its original advisory function, and it became involved in the logistics of running both laboratories and collection sites. However, the estimated number of labs and locations remained the same. This changed in March 2021, when the University of Illinois System entered into an Intergovernmental Agreement with the Illinois Department of Public Health to offer testing to every school district, community college, and public university in Illinois, as well as community testing sites for the general public throughout the state. There are 853 school districts covering 3,977 with 1.9 million students in Illinois. As of October 2022, the company had performed over 6.5 million tests at over 1,700 sites in Illinois, including the governor's office, the state legislature, and the United States District Court for the Northern District of Illinois; engaged 12 CLIA or CAP-certified laboratories; and built a transportation network covering 80,000 square miles.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。